Eli Lilly and (LLY) Stock Forecast, Price & News

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last year. There are currently 1 sell rating, 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LLY shares.
View LLY analyst ratings or view top-rated stocks.

15 brokers have issued 12-month price objectives for Eli Lilly and's shares. Their LLY share price forecasts range from $278.00 to $507.00. On average, they expect the company's stock price to reach $425.05 in the next twelve months. This suggests that the stock has a possible downside of 4.7%.
View analysts price targets for LLY or view top-rated stocks among Wall Street analysts.

Eli Lilly and's stock was trading at $365.84 at the beginning of the year. Since then, LLY stock has increased by 21.9% and is now trading at $446.06.
View the best growth stocks for 2023 here.

Eli Lilly and saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 6,200,000 shares, a decrease of 18.1% from the April 15th total of 7,570,000 shares. Based on an average daily volume of 3,250,000 shares, the short-interest ratio is currently 1.9 days. Currently, 0.7% of the company's shares are short sold.
View Eli Lilly and's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our LLY earnings forecast.

Eli Lilly and Company (NYSE:LLY) issued its quarterly earnings data on Thursday, April, 27th. The company reported $1.62 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.73 by $0.11. The business earned $6.96 billion during the quarter, compared to analyst estimates of $6.87 billion. Eli Lilly and had a trailing twelve-month return on equity of 61.42% and a net margin of 20.54%. Eli Lilly and's revenue for the quarter was down 10.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.62 EPS.
Read the conference call transcript.

Eli Lilly and announced a quarterly dividend on Monday, May 1st. Shareholders of record on Monday, May 15th will be given a dividend of $1.13 per share on Friday, June 9th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 1.01%. The ex-dividend date of this dividend is Friday, May 12th.
Read our dividend analysis for LLY.

ETFs with the largest weight of Eli Lilly and (NYSE:LLY) stock in their portfolio include Harbor Health Care ETF (MEDI), Invesco S&P 500 Momentum ETF (SPMO), Horizon Kinetics Medical ETF (MEDX), QRAFT AI-Enhanced U.S. Large Cap Momentum ETF (AMOM), Invesco Dynamic Pharmaceuticals ETF (PJP), Health Care Select Sector SPDR Fund (XLV), iShares U.S. Healthcare ETF (IYH) and VanEck Pharmaceutical ETF (PPH).

Eli Lilly and (NYSE:LLY) pays an annual dividend of $4.52 per share and currently has a dividend yield of 1.02%. The company has been increasing its dividend for 9 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 71.86%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LLY will have a dividend payout ratio of 37.45% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LLY.

Eli Lilly and updated its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of $8.65-$8.85 for the period, compared to the consensus earnings per share estimate of $8.45. The company issued revenue guidance of $31.20 billion-$31.70 billion, compared to the consensus revenue estimate of $30.64 billion.

399 employees have rated Eli Lilly and Chief Executive Officer David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Eli Lilly and's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Lilly Endowment Inc. (10.79%), BlackRock Inc. (6.91%), State Street Corp (3.50%), FMR LLC (3.37%), Price T Rowe Associates Inc. MD (2.39%) and Wellington Management Group LLP (2.14%). Insiders that own company stock include Acquisition Corp Kearny, Alfonso G Zulueta, Alonzo Weems, Anne E White, Donald A Zakrowski, Ilya Yuffa, Jackson P Tai, Lilly Endowment Inc, Marschall S Runge, Melissa S Barnes and Patrik Jonsson.
View institutional ownership trends.

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LLY stock can currently be purchased for approximately $446.06.

Eli Lilly and (NYSE:LLY) has a market capitalization of $423.43 billion and generates $28.54 billion in revenue each year. The company earns $6.24 billion in net income (profit) each year or $6.29 on an earnings per share basis.

The company employs 39,000 workers across the globe.

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The official website for the company is www.lilly.com. The company can be reached via phone at (317) 276-2000, via email at johnson_philip_l@lilly.com, or via fax at 317-276-4878.